



## **Update from IARC**

**Kurt Straif**

**International Agency for Research on Cancer  
Lyon, France**

**Collegium Ramazzini Meeting, Carpi 2017**

International Agency for Research on Cancer



## Welding and occupational exposure to welding fumes, Vol 118

- IARC Monographs V118, 03/2017, *welding fumes are carcinogenic to humans* (Group 1), based on *sufficient evidence* for lung cancer
- Worldwide, an **estimated 11 million workers** have a **job title of welder**, and around **110 million additional workers** probably incur **welding-related exposures**.
- Welding can involve exposures to fumes, gases, UV radiation and electromagnetic fields and co-exposures to asbestos and solvents
- Most case–control studies showed positive associations, with risks for ocular melanoma increased by between 2-fold and 10-fold
- Sufficient evidence for the carcinogenicity of UV radiation and ocular melanoma.

## Welding and occupational exposure to welding fumes, Vol 118

- 20 case–control studies and ca. 30 cohort studies, reported increased risks of lung cancer in welders or other workers exposed to welding fumes.
- Exposure–response associations with indices of longer or greater cumulative exposure to welding fumes reported in several studies,
- Positive associations persisted after adjusting directly or indirectly for smoking, asbestos co-exposure, or both; restricting to non-smokers and in cohorts with low or minimal asbestos exposure.
- Positive associations for occupation as a welder and kidney cancer
- Strong evidence suggests that welding fumes induce chronic inflammation and are immunosuppressive.

# Prevention of occupational cancer

- Guy Ryder, DG ILO
- Michel Servoz, Head, DG EMPLOI , EU
- Sergio Iavicoli, Secretary General, ICOH
- Pirkko Mattila, Minister of Social Affairs and Health, Finland
- Sam Tan, Minister of State, Prime Minister's Office, Singapore
- Sun Huashan, Vice Minister, State Administration of Work Safety, China
- Christa Sedlatschek, Director, EU OSHA; Kurt Straif, IARC

## ICOH Mini-symposium on Prevention of occupational cancer

*Moderators: Jukka Takala, Sergio Iavicoli, Jorma Rantanen*

- Michel Servoz, France
- Pirkko Mattila, Finland
- Identification of occupational carcinogens. The IARC monographs as the basis for estimating the burden of occupational cancer.

## WHO-ILO Estimating the burden of occupational diseases




**Future forms of work  
and impact on occupational  
safety and health**

# Pentachlorophenol, Vol 117

- Sufficient evidence of cancer in humans (Non-Hodgkin lymphoma)
- Sufficient evidence of cancer in animals;
- Strong evidence of multiple KC,
  - metabolically activated to electrophilic benzoquinones and redox-cycling semiquinones,
  - induces oxidative stress,
  - is genotoxic,
  - is anti-estrogenic, and
  - alters cell signalling, apoptosis, and proliferation.
- **Group 1 carcinogen**

International Agency for Research on Cancer

# Epidemiologic data for occupational carcinogen identification and risk assessment



# Pooled analyses of workers monitored for lead exposure

- Investigate whether **inorganic lead** is a carcinogen among adults
- 3 cohorts of **lead-exposed workers with blood lead** data (USA, Finland, UK), including > 88 000 workers and >14 000 deaths.
- Exposure metric was **maximum blood lead**

**Table 4** Categorical and continuous results of mortality by blood lead category for selected cancers\*

Cause	Number of deaths by lead category		HRT	95% CI
		Lead category, µg/dL		
Bladder cancer n=96	15	20 to <30	1.02	0.54 to 1.93
	14	30 to <40	1.40	0.71 to 2.76
	40	40+	1.86	1.04 to 3.33
Brain cancer (including benign) n=111	26	20 to <30	1.31	0.79 to 2.17
	14	30 to <40	1.05	0.55 to 1.99
	33	40+	1.42	0.83 to 2.43
Larynx cancer n=39	6	20 to <30	1.21	0.41 to 3.54
	4	30 to <40	0.97	0.28 to 3.35
	21	40+	2.69	1.07 to 6.76
Lung cancer n=1333	271	20 to <30	1.39	1.19 to 1.64
	214	30 to <40	1.54	1.29 to 1.84
	500	40+	1.78	1.51 to 2.08
Kidney cancer n=128	24	20 to <30	0.89	0.54 to 1.45
	9	30 to <40	0.50	0.24 to 1.03
	42	40+	1.21	0.74 to 1.97
Stomach cancer n=195	57	20 to <30	1.62	1.13 to 2.32
	18	30 to <40	0.84	0.49 to 1.44
	53	40+	1.09	0.70 to 1.67



# Pooled analyses of workers monitored for lead exposure

- Investigate whether **inorganic lead** is a carcinogen among adults
- 3 cohorts of **lead-exposed workers with blood lead** data (USA, Finland, UK), including > 88 000 workers and >14 000 deaths.
- Exposure metric was **maximum blood lead**
- **Strong positive mortality trends, with increasing BL level,** for several outcomes in **internal analysis**.
- Many of these outcomes associated with **smoking**
- Small sub sample of US cohort (n=115)  
**no association between smoking and maximum blood lead.**
- Borderline trend for **brain cancer, not associated with smoking.**

# Exposure to asbestos and cholangiocarcinoma

- Case-control study nested in the Nordic Occupational Cancer (NOCCA) cohort.
- 1,458 intrahepatic CC (ICC) and 3,972 extrahepatic (ECC) cases
- Each case individually matched by birth year, gender, and country to 5 population controls.
- Cumulative exposure to asbestos by applying NOCCA job exposure matrix to censuses data on occupation (conducted in 1960, 1970, 1980/81, and 1990).
- Exposure-response trend for ICC  
No association between asbestos exposure and ECC

Cumulative exposure to asbestos and risk of **intrahepatic cholangiocarcinoma**. Logistic regression

(matching variables: year of birth, gender, country) adjusted by printing industry work

	Cases	Controls	OR	(95%CI) <sup>a</sup>	P trend	BIC
Lag period	N=1,458	N=6,773				
<b>No lag</b>					<b>0.004</b>	<b>5036.3</b>
0 f/ml * years	1,171	5,548	1.0	(Ref.)		
0.1–1.1 f/ml * years	144	641	1.2	(1.0–1.4)		
1.2–14.9 f/ml * years	109	480	1.2	(1.0–1.5)		
≥15.0 f/ml * years	34	104	1.7	(1.1–2.6)		
<b>20-year lag</b>					<b>0.003</b>	<b>5035.4</b>
0 f/ml * years	1,196	5,663	1.0	(Ref.)		
0.1–1.1 f/ml * years	133	586	1.2	(1.0–1.5)		
1.2–14.9 f/ml * years	110	477	1.2	(1.0–1.5)		
≥15.0 f/ml * years	19	47	2.1	(1.2–3.7)		